Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Th 9 cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    137 result(s) found for: Th 9 cells. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2012-000633-39 Sponsor Protocol Number: FEC-TH Start Date*: 2012-05-21
    Sponsor Name:Fundación para la Formación e Investigación Sanitaria
    Full Title: Extracorporeal photopheresis in liver transplantation. Clinical trial phase I/II safety and efficacy in patients with progressive withdrawal of immunosuppression.
    Medical condition: Liver transplantation more than 2 years of evolution to complications of immunosuppression.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001452-55 Sponsor Protocol Number: 204852 Start Date*: 2018-11-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biolog...
    Medical condition: Chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003567-10 Sponsor Protocol Number: 217023 Start Date*: 2021-12-23
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS
    Full Title: A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonuc...
    Medical condition: Hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003597-10 Sponsor Protocol Number: MK-8591A-028 Start Date*: 2020-07-15
    Sponsor Name:MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >=12 to <18 Years ...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005834-19 Sponsor Protocol Number: GBG44 Start Date*: 2007-10-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer
    Medical condition: breast cancer, primary systemic therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002920-41 Sponsor Protocol Number: StelaraPG01 Start Date*: 2012-01-04
    Sponsor Name:University Hospital Tübingen
    Full Title: Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients.
    Medical condition: Patients with a clinical diagnosis of Pyoderma gangrenosum
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037634 Pyoderma gangenosum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014593-18 Sponsor Protocol Number: CT-2008-01 Start Date*: 2009-12-07
    Sponsor Name:CureTech
    Full Title: CT-2008-01: Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + CT-011 versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously ...
    Medical condition: This study will enroll patients with untreated, metastatic colorectal carcinoma who are eligible for first line FOLFOX therapy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001153-10 Sponsor Protocol Number: X4P-001-103 Start Date*: 2020-02-05
    Sponsor Name:X4 Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
    Medical condition: WHIM Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010512 Congenital immunodeficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) ES (Ongoing) PL (Completed) AT (Completed) DE (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002245-11 Sponsor Protocol Number: LTF-303 Start Date*: 2013-11-12
    Sponsor Name:bluebird bio, Inc.
    Full Title: Long-term Follow-up of Subjects Treated with Ex Vivo Gene Therapy using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector
    Medical condition: Subjects treated with gene therapy drug products in a bluebird bio-sponsored or associated clinical study will be invited to participate in this long-term follow-up study to monitor the safety and ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10055579 Sickle-cell beta thalassemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000313-40 Sponsor Protocol Number: GS-US-236-0112 Start Date*: 2015-01-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1...
    Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002857-31 Sponsor Protocol Number: SB12-3003 Start Date*: 2019-09-09
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB12 (proposed eculizumab biosimilar) and Soliris® in Subjects ...
    Medical condition: Paroxysmal Nocturnal Haemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-009256-20 Sponsor Protocol Number: OMB110928 Start Date*: 2009-12-23
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) SE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) HU (Completed) PL (Prematurely Ended) DE (Prematurely Ended) AT (Completed) EE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002852-19 Sponsor Protocol Number: BO42533 Start Date*: 2021-03-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB AND ATEZOLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL ...
    Medical condition: Squamous cell carcinoma of the head and neck (SCCHN).
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004122-33 Sponsor Protocol Number: HGB-207 Start Date*: 2016-11-10
    Sponsor Name:bluebird bio, Inc.
    Full Title: A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β-Thalassemia, who do not have β0/β0 Genotype, by Transplantation of Autologous ...
    Medical condition: This study will enroll subjects with transfusion dependent beta-thalassemia, who do not have beta0/beta0 genotype, defined by a history of at least 100 mL/kg/year of packed red blood cells (pRBCs) ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GR (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004895-21 Sponsor Protocol Number: WO42017 Start Date*: 2020-06-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1−POSITIVE CERVICAL CANCER.
    Medical condition: Cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003466-20 Sponsor Protocol Number: ARORAGE-1001 Start Date*: 2023-06-01
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Phase 1/2a Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004019-11 Sponsor Protocol Number: Troika Start Date*: 2018-07-03
    Sponsor Name:Prestige BioPharma Pte Ltd
    Full Title: A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast...
    Medical condition: Non-metastatic, unilateral, newly diagnosed, operable early breast cancer (EBC) of clinical stage II and III including inflammatory breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) EE (Completed) HU (Completed) BG (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001311-36 Sponsor Protocol Number: R2810-ONC-16113 Start Date*: 2018-02-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patie...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) LT (Completed) IT (Completed) AT (Completed) PL (Trial now transitioned) HR (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002221-29 Sponsor Protocol Number: VIT-2763-THAL-201 Start Date*: 2020-02-25
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of...
    Medical condition: Non-transfusion Dependent Beta-thalassaemia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074355 Non-transfusion dependent thalassaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 15:28:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA